Home Cart Sign in  
Chemical Structure| 520-12-7 Chemical Structure| 520-12-7

Structure of Pectolinarigenin
CAS No.: 520-12-7

Chemical Structure| 520-12-7

*Storage: {[sel_prStorage]}

*Shipping: {[sel_prShipping]}

,{[proInfo.pro_purity]}

Pectolinarigenin is a dimethoxyflavone extracted from the leaves of Linaria vulgaris Mill and it has been found to specifically bind to the nuclear receptor RARγ (IC50 = 3.42 μM) to activate the JNK signaling pathway and induce apoptosis.

4.5 *For Research Use Only !

{[proInfo.pro_purity]}
Cat. No.: {[proInfo.prAm]} Purity: {[proInfo.pro_purity]}

Change View

Size Price VIP Price

US Stock

Global Stock

In Stock
{[ item.pr_size ]} Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price, item.vip_usd) ]}

US Stock: ship in 0-1 business day
Global Stock: ship in 5-7 days

  • {[ item.pr_size ]}

In Stock

- +

Please Login or Create an Account to: See VIP prices and availability

US Stock: ship in 0-1 business day
Global Stock: ship in 2 weeks

  • 1-2 Day Shipping
  • High Quality
  • Technical Support
Product Citations

Alternative Products

Product Details of Pectolinarigenin

CAS No. :520-12-7
Formula : C17H14O6
M.W : 314.29
SMILES Code : O=C1C=C(C2=CC=C(OC)C=C2)OC3=CC(O)=C(OC)C(O)=C13
MDL No. :MFCD00017444
InChI Key :GPQLHGCIAUEJQK-UHFFFAOYSA-N
Pubchem ID :5320438

Safety of Pectolinarigenin

GHS Pictogram:
Signal Word:Warning
Hazard Statements:H302-H315-H319-H335
Precautionary Statements:P261-P305+P351+P338

Isoform Comparison

Biological Activity

In Vitro:

Cell Line
Concentration Treated Time Description References
Osteosarcoma cell lines 0, 10, 20, 50 µM 24 hours Inhibits STAT3 activity Cell Death Dis. 2018 Sep 5;9(9):902
143B cells 0, 5, 10, 20, 50 µM 24 hours Inhibits STAT3 activity Cell Death Dis. 2018 Sep 5;9(9):902
MKN-28 cells 0, 25, 50, 75, 100, 150, and 200 µM 24 hours PEC significantly reduced the viability of MKN-28 cells with an IC50 of approximately 96.88 μM. Nutrients. 2018 Oct 30;10(11):1596
AGS cells 0, 25, 50, 75, 100, 150, and 200 µM 24 hours PEC significantly reduced the viability of AGS cells with an IC50 of approximately 124.79 μM. Nutrients. 2018 Oct 30;10(11):1596
TCMK-1 cells 25, 50, 100, 150, 300 µM 24 hours To evaluate the effect of PEC on uric acid-induced inflammation and fibrosis in TCMK-1 cells. Results showed that PEC significantly suppressed the expression of IL-6, TNF-α, and FABP4, and reduced the fibrotic expression of α-SMA, FN, and Col I. Front Pharmacol. 2022 Jan 27;12:792139
HepG2 cells 0.1, 1.0, 10 µM 24 hours PG significantly increased the expression of HO-1, NQO-1, and AKR1B10, inducing antioxidant enzymes via the Nrf2/ARE pathway Antioxidants (Basel). 2022 Mar 30;11(4):675
Mouse NSC-34 motor neuron cell lines 2.5 and 5 µM 24 hours PLG treatment significantly increased the viability of PR50-expressing cells, reduced ROS production and apoptosis, and restored mitochondrial membrane potential. Antioxidants (Basel). 2023 Nov 16;12(11):2008
MKN28 cells 25, 50, 75, 100, 125, 150 µM 24 hours PEC significantly inhibited MKN28 cell growth in a dose-dependent manner with an IC50 of 96.88 μM. Nutrients. 2018 Aug 8;10(8):1043
AGS cells 25, 50, 75, 100, 125, 150 µM 24 hours PEC significantly inhibited AGS cell growth in a dose-dependent manner with an IC50 of 124.79 μM. Nutrients. 2018 Aug 8;10(8):1043
MCF-7 0–40 µM 24, 48, 72 hours Pectolinarigenin significantly inhibited the proliferation and migration of MCF-7 cells and impaired cell invasion by down-regulating phosphorylated-Stat3, MMP-2, and MMP-9 while up-regulating the expression of TIMP2. Front Pharmacol. 2019 Oct 10;10:1195
MDA-MB-231 0–40 µM 24, 48, 72 hours Pectolinarigenin significantly inhibited the proliferation and migration of MDA-MB-231 cells and impaired cell invasion by down-regulating phosphorylated-Stat3, MMP-2, and MMP-9 while up-regulating the expression of TIMP2. Front Pharmacol. 2019 Oct 10;10:1195
4T1 0–40 µM 24, 48, 72 hours Pectolinarigenin significantly inhibited the proliferation and migration of 4T1 cells and impaired cell invasion by down-regulating phosphorylated-Stat3, MMP-2, and MMP-9 while up-regulating the expression of TIMP2. Front Pharmacol. 2019 Oct 10;10:1195

In Vivo:

Species
Animal Model
Administration Dosage Frequency Description References
C57BL/6J mice Hyperuricemic nephropathy model Oral 25 and 50 mg/kg Daily administration for 4 weeks To evaluate the nephroprotective effects of PEC in hyperuricemic nephropathy mice. Results showed that PEC significantly lowered serum uric acid levels, improved kidney function, alleviated renal inflammation and fibrosis, and inhibited the activation of TGF-β/SMAD3 and JAK2/STAT3 signaling pathways. Front Pharmacol. 2022 Jan 27;12:792139
Balb/c mice 4T1 breast cancer model Intraperitoneal injection 25 mg/kg, 50 mg/kg Once daily for 10 days Pectolinarigenin significantly inhibited breast cancer metastasis to lungs without affecting the tumor growth of incubated 4T1 breast cancer cells. Additionally, Pectolinarigenin could recruit CD8+ T cells to mediate tumor immune response. Front Pharmacol. 2019 Oct 10;10:1195

Protocol

Bio Calculators
Preparing Stock Solutions 1mg 5mg 10mg

1 mM

5 mM

10 mM

3.18mL

0.64mL

0.32mL

15.91mL

3.18mL

1.59mL

31.82mL

6.36mL

3.18mL

References

 

Historical Records

Categories